Tokyo Women's Medical University Journal
Online ISSN : 2432-6186

This article has now been updated. Please use the final version.

Effective Valproic Acid Treatment in Motor Function is Caused by Possible Mechanism of Elevated Survival Motor Neuron Protein Related with Splicing Factor Gene Expression in Spinal Muscular Atrophy
Kozue TakanoToshitaka UchiyamaNoriko OtsukiHisahide NishioYuji KuboReiko ArakawaToshio SaitoYasuhiro TakeshimaKotaro YugeToshio IkedaZenichiro KatoTakashi NakajimaKayoko Saito
Author information
JOURNAL OPEN ACCESS Advance online publication
Supplementary material

Article ID: 2021020

Details
Abstract

Background: Spinal muscular atrophy (SMA) is a lower motor neuron disease caused by SMN1. Several clinical trials have indicated that valproic acid (VPA) benefits a limited number of SMA patients. To clarify the difference in VPA responsiveness and elucidate the mechanism, we analyzed gene expression changes by VPA treatment in Japanese pediatric patients using data from clinical trials.

Methods: To identify VPA responders, we correlated the changes in motor function and survival motor neuron (SMN) protein levels. To determine the effects of VPA on gene expression profiles, a microarray analysis was performed. The Gene Ontology (GO) analysis evaluated statistically overexpressed GO terms within a group of genes.

Results: The group with significant improvement showed elevated SMN protein levels following VPA administration, whereas that with the highest SMN levels at baseline did not improve immediately. GO analysis suggested that specific factors contributed to the correlation between changes in motor function and the SMN protein levels, including splicing factors HNRNPC and SNRNP70.

Conclusions: This is the first study to indicate that the time for VPA effectiveness varies among individuals and is associated with SMN protein levels at baseline and expression changes in splicing factor genes.

Clinical Trials Registry of the Center for Clinical Trials, Japan Medical Association, a registry of the Japan Primary Registries Network certified by the World Health Organization as a primary registry (registration numbers: SMART01 trial, JMA-II A00190; SMART02 trial, JMA-II A00231; SMART03 trial, JMA-II A00259).

Content from these authors
© 2022 Society of Tokyo Women's Medical University

This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.
https://creativecommons.org/licenses/by/4.0/deed.ja
feedback
Top